GOVX · GeoVax Labs, Inc.

GeoVax Labs reported a Q1 2026 net loss of $5.3 million, nearly flat compared to $5.4 million in Q1 2025, primarily due to the absence of $1.6 million in government contract revenue from the prior year. The BARDA/RRPV Project NextGen award for GEO-CM04S1 COVID-19 vaccine was terminated for convenience in April 2025, eliminating comparable revenue and contributing to lower research and development expenses of $3.9 million versus $5.4 million, reflecting reduced spending on discontinued BARDA activities and GEO-CM04S1 clinical work. General and administrative costs also declined to $1.4 million from $1.7 million, driven by lower investor relations consulting and stock-based compensation. CEO David A. Dodd emphasized strategic focus on GEO-MVA, the Modified Vaccinia Ankara vaccine for mpox and smallpox, with execution activities underway for a Phase 3 immunobridging study under an EMA-aligned expedited pathway. Key milestones include CRO selection, cGMP material release, and plans to enroll ~500 participants to demonstrate non-inferiority to an approved MVA comparator, positioning GEO-MVA to address global supply constraints and biodefense needs. In parallel, the Gedeptin immuno-oncology platform advances with an exclusive Emory University license for combinations with checkpoint inhibitors, targeting immune sensitization in solid tumors like head and neck cancer. Cash reserves dwindled to $1.3 million from $3.1 million at year-end, underscoring funding needs amid prioritization of GEO-MVA for its regulatory clarity and market potential.